QTI

QT Imaging Holdings, Inc. (QTI) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. QT Imaging Holdings, Inc. is a medical device company developing and commercializing the Breast Acoustic CT Scanner, a low-frequency sound wave imaging system. The company is classified as a smaller reporting company and an emerging growth company. As of June 30, 2026, the company had an accumulated deficit of $67.5 million and continues to incur net operating losses.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 103% year-over-year for the quarter and 116% for the six-month period, driven by the sale of 15 scanners in Q2 2026 (vs. 8 in Q2 2025) and 28 scanners in the first half of 2026 (vs. 14 in 2025).
• Operating Expenses: Total operating expenses rose 72% for the quarter and 74% for the six-month period, primarily due to increased headcount, merit-related salary increases, and higher professional service costs.
• Debt Extinguishment Loss: A significant non-cash loss of $8.3 million was recorded in the second quarter of 2026 due to the modification of the Lynrock Lake Term Loan, which was accounted for as a debt extinguishment. This resulted in the write-off of unamortized debt discount.
• Interest Expense: Net interest expense increased 97% for the quarter due to higher interest rates and debt discount amortization on the Lynrock Lake Term Loan.

Guidance, Outlook, and Risks

Capital Resources and Liquidity: The company raised approximately $8.9 million in net proceeds from an underwritten public offering in May 2026. Management believes current cash, the extended Lynrock Lake Term Loan (maturity extended to March 2029), and expected revenue from distribution agreements are sufficient to fund operations for at least the next 12 months.

Outlook and Milestones:

• Distribution Agreements: The company has signed agreements with NXC Imaging (60 scanners MOQ for 2026), Gulf Medical Co. (Saudi Arabia), and Al Naghi Medical Co. (UAE), representing potential revenue of over $100 million combined.
• Earnout Liability: The company faces a potential earnout obligation of up to 3 million shares if specific revenue ($30 million) or stock price ($45.00) milestones are met by September 30, 2026.

Material Risks:

• Geopolitical Disruption: Ongoing military conflicts in the Middle East (specifically U.S. and Israeli operations against Iran) have disrupted shipping through the Strait of Hormuz. The company is currently unable to ship scanners to its distributors in Saudi Arabia and the UAE, which could materially impact revenue and liquidity.
• Profitability: The company has a history of net losses and expects to continue incurring losses as it expands R&D and commercialization efforts.
• Dilution: Significant numbers of warrants and options are outstanding, including a large warrant issued to Lynrock Lake, which could lead to substantial dilution upon exercise.

Investor Verification Checklist

• Shipping Status: Verify the current status of shipments to Gulf Medical and Al Naghi given the geopolitical risks in the Middle East and the closure of the Strait of Hormuz.
• Debt Covenants: Review the specific covenants of the Lynrock Lake Term Loan, particularly the mandatory prepayment clauses tied to accounts receivable collections and extraordinary receipts.
• Earnout Probability: Assess the likelihood of meeting the $30 million revenue or $45.00 stock price milestones required to trigger the issuance of 833,333 to 1,000,000 earnout shares by September 2026.
• Inventory Levels: Inventory increased significantly to $9.9 million (from $5.0 million year-over-year); verify if this aligns with confirmed orders or represents potential obsolescence risk.
• Warrant Liability: Monitor the fair value of the warrant liability ($187k) and the potential dilution from the Lynrock Lake Warrant (25.3 million shares exercisable at ~$0.96).